Compounders Research Compare

Actuate Therapeutics Inc(ACTU)

Biotechnology · Fort Worth, TX

$0.83-0.05 (-5.59%)

Delayed quote: Oct 6, 2026, 1:00 PM EDT

About Actuate Therapeutics Inc

Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas.

Fort Worth, TX

12 employees

actuatetherapeutics.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Daniel Schmitt

View full financials

EV/Sales Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/Sales ratio is N/A as of 2026-10-06T17:05:30.190Z.

Stored calculation inputs

Calculation as of: 2026-10-06T17:05:30.190Z.

Quote observation: 2026-10-06T17:00:20.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 19,762,754
Total debt · period ending 2026-06-30: 404,991
Cash · period ending 2026-06-30: 4,425,841
TTM revenue · period ending 2026-06-30: 0

FMP input reference: a29a88061d86e64317c53e71c63756e58f7ffa0b55551e6148327154cc786467

EV/EBITDA|P/S Ratio|Revenue|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

ACTU EV/Sales Ratio Metrics

EV/SALES RATIO

N/A

ACTU Competitors' EV/Sales Ratio

Actuate Therapeutics Inc

Current

Market Cap

$19.76M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

P3 Health Partners Inc.

Market Cap

$19.67M

EV/Sales Ratio

0.09x

TTM Avg

0.07x

3Y Avg

0.10x

5Y Avg

0.22x

NextCure, Inc.

Market Cap

$21.17M

EV/Sales Ratio

N/A

TTM Avg

15.07x

3Y Avg

94.54x

5Y Avg

94.54x

Quantum BioPharma Ltd.

Market Cap

$20.80M

EV/Sales Ratio

N/A

TTM Avg

207.31x

3Y Avg

4938.40x

5Y Avg

4938.40x

Neuphoria Therapeutics Inc.

Market Cap

$18.65M

EV/Sales Ratio

N/A

TTM Avg

13.65x

3Y Avg

401.05x

5Y Avg

54100.66x

Modular Medical, Inc.

Market Cap

$21.76M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Cosmos Health Inc.

Market Cap

$17.72M

EV/Sales Ratio

0.43x

TTM Avg

0.52x

3Y Avg

0.46x

5Y Avg

0.60x

Estrella Immunopharma, Inc.

Market Cap

$17.60M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Aytu BioPharma, Inc.

Market Cap

$22.11M

EV/Sales Ratio

0.24x

TTM Avg

0.37x

3Y Avg

0.25x

5Y Avg

0.21x

PAVmed Inc.

Market Cap

$17.23M

EV/Sales Ratio

272.49x

TTM Avg

308.82x

3Y Avg

115.81x

5Y Avg

143.55x

NAME	MARKET CAP	EV/SALES RATIO	TTM	3Y	5Y
Actuate Therapeutics Inc (ACTU)	$19.76M	N/A	N/A	N/A	N/A
P3 Health Partners Inc. (PIII)vs ›	$19.67M	0.09x	0.07x	0.10x	0.22x
NextCure, Inc. (NXTC)vs ›	$21.17M	N/A	15.07x	94.54x	94.54x
Quantum BioPharma Ltd. (QNTM)vs ›	$20.80M	N/A	207.31x	4938.40x	4938.40x
Neuphoria Therapeutics Inc. (NEUP)vs ›	$18.65M	N/A	13.65x	401.05x	54100.66x
Modular Medical, Inc. (MODD)vs ›	$21.76M	N/A	N/A	N/A	N/A
Cosmos Health Inc. (COSM)vs ›	$17.72M	0.43x	0.52x	0.46x	0.60x
Estrella Immunopharma, Inc. (ESLA)vs ›	$17.60M	N/A	N/A	N/A	N/A
Aytu BioPharma, Inc. (AYTU)vs ›	$22.11M	0.24x	0.37x	0.25x	0.21x
PAVmed Inc. (PAVM)vs ›	$17.23M	272.49x	308.82x	115.81x	143.55x

Understanding EV/Sales

Enterprise Value (EV) = Market Cap + Total Debt - Cash

Sales = Total Revenue (TTM)

EV/Sales is commonly used because:

It works for unprofitable companies where P/E doesn't apply
Revenue is harder to manipulate than earnings
It supports comparisons across companies at different profitability stages
It is frequently used for software and other revenue-growth-focused companies

Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.

EV/Sales Ratio Formula & Definition

EV/Sales = Enterprise Value / Revenue (TTM)

Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/EBITDA P/S Ratio Revenue All Metrics